Immunotoxins have now been designed to contain only the elements needed to recognize and kill tumor cells. There is now a notable body of evidence suggesting that immunotoxins may play an important therapeutic role in the treatment of hematologic malignancies. Challenges ahead are to render the toxin portion of the immunotoxin less immunogenic, to prevent the development of neutralizing antibodies and ensure that more cycles of treatment can be given. The utility of immunotoxins in solid tumors may be hampered by poor uptake of the therapeutic proteins, although potential means to overcome this and other barriers are being defined.

 

Charles A. Butts, MD	David Carbone, MD, PhD	David Jablons, MD	Håkan Mellstedt, MD, PhD	Pedro Romero, MD

Upcoming Targeted Therapy Meetings

Stanley J. Korsmeyer Symposium: Cell Death and Cancer—Opportunities for Therapeutic Intervention

January 25-26, 2007
Boston, Massachusetts

Oncogenomics 2007: Dissecting Cancer Through Genome Research

January 31-February 3, 2007
Phoenix, Arizona

Science Driving New Therapies in Cancer Medicine: A Special AACR Course for the Community Oncologist Investigator

January 31-February 3, 2007
Phoenix, Arizona

PI 3-Kinase Signaling Pathways in Disease

February 15-20, 2007
Santa Fe, New Mexico

5th International Symposium on Targeted Anticancer Therapies

March 8-10, 2007
Amsterdam, The Netherlands

 

ATCT is funded by an unrestricted educational grant from EMD Pharmaceuticals, Inc.

Current Issue

Feature

Immunotoxins: The Next Generation

Notes & Commentary

New Cancer-Related Mutations Found in Breast & Colon Cancers

Reviews & Reports

News from the AACR’s Molecular Diagnostics in Cancer Therapeutic Development Meeting

News from the AACR’s Frontiers in Cancer Prevention Research Meeting

Panitumumab approved for metastatic colorectal carcinoma

Bevacizumab use expanded to lung cancer

Histone deactylase inhibitor, vorinostat, now available

Trastuzumab expanded to adjuvant use in breast cancer

Imatinib: New uses approved, cardiac warning issued

Digest

Targeted mouse models useful in testing novel anticancer agents

ATCT Article Reprints

Articles in PDF format
are available for download for the duration of the current issue

Slides

Angiogenesis Inhibition: A Targeted Approach to Cancer Therapy
PowerPoint slides, notes and references included

Search Previous Issues

 

Publisher:

© NCM Nexus, Inc.
Contact | Disclaimer | Privacy Policy

ATCT CME Activities

Promising Targeted Modalities in NSCLC

Rafael Rosell, MD

 

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates each educational activity for a maximum of 1 Category 1 Credit toward the AMA Physician’s Recognition Award. Each physician should claim those credits that he/she actually spent in the educational activity.

These CME activities were planned and produced in accordance with the ACCME Essentials.